BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 11865634)

  • 21. [Clinical study on the inhibitory effect of a 5-HT3 antagonist, granisetron, for nausea and vomiting induced by chemotherapy (CHOP, VEPA, high-dose ETP) for non-Hodgkin's lymphoma].
    Sasai Y; Misawa S; Iwai T; Tamura A; Nakazawa N; Ueda Y; Kaneko H; Horiike S; Yokota S; Taniwaki M; Kashima K; Tsuda S; Ookawara Y; Nakao M; Nakagawa H; Fujii H
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):723-9. PubMed ID: 9571970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
    Nukariya N; Niitani H; Taguchi T; Furue H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1347-57. PubMed ID: 1386976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis.
    Sabbatini R; Federico M; Baldini L; Barbieri F; Maiolo MT; Silingardi V
    Haematologica; 1995; 80(5):416-20. PubMed ID: 8566881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis.
    Rosso R; Campora E; Cetto G; Fosser V; Marangolo M; Oliva C
    Anticancer Res; 1991; 11(2):937-9. PubMed ID: 1829602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
    Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Multi-drug antiemetic treatment and effect of treatment duration of concurrent steroids--for complete control of chemotherapy-induced nausea/vomiting in gynecological cancer].
    Fujii T; Nakata N; Shiroyama Y; Sawasaki T; Tanimoto H; Shigemasa K; Kioka H; Naito H
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2245-52. PubMed ID: 9422069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
    Tanimura S; Banba J; Tomoyasu H; Masaki M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
    J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial].
    Zeng W; Zhou J; Zhang P
    Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):294-7. PubMed ID: 7587900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors].
    Kitada M; Sawaragi I
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):87-91. PubMed ID: 8546476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
    Dix S; Cord M; Howard S; Coon J; Belt R; Geller R
    Bone Marrow Transplant; 1999 Sep; 24(5):561-6. PubMed ID: 10482943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
    Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ
    N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of granisetron rescue therapy for nausea and vomiting induced by cancer chemotherapies in urogenital malignant tumor].
    Takigawa H; Naruo S; Kanayama H; Kagawa S; Yokoseki H; Inai T; Sumitani H; Sakurai N; Ogawa I; Akazawa S
    Gan To Kagaku Ryoho; 1996 Jun; 23(7):899-903. PubMed ID: 8678539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].
    Ariyoshi Y; Ota K; Taguchi T; Furue H; Niitani H; Tsukagoshi S; Ikeda M; Akasaka Y; Ohta J; Suminaga M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2057-70. PubMed ID: 1417014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical evaluation of granisetron hydrochloride for nausea and vomiting induced by oral anticancer drugs].
    Togo S; Kunisaki C; Moriwaki Y; Yamaguchi S; Ichikawa Y; Oki S; Shimada H; Takahashi M; Ike H; Fukushima T; Obi Y; Kubo A; Takahashi T; Hosoi H; Fukazawa S; Suda T; Yamazaki Y
    Gan To Kagaku Ryoho; 2000 Jul; 27(7):1021-8. PubMed ID: 10925688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antiemetic effect of ondansetron in recurrent chemotherapy with cisplatin].
    Marty M; Richard A; d'Allens H
    Bull Cancer; 1993 Jul; 80(7):618-23. PubMed ID: 8204942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
    Shih V; Wan HS; Chan A
    Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive combination chemotherapy (TTL-I protocol) of large cell and immunoblastic lymphomas--long-term observation.
    Koza I; Mardiak J; Bohunický L; Svancárová L; Fuchsberger P; Gyárfás J; Horák I; Spánik S; Sufliarsky J; Thalmeinerová Z
    Neoplasma; 1992; 39(1):43-7. PubMed ID: 1382234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total control of chemotherapy induced emesis.
    Helson L
    Anticancer Res; 1992; 12(6B):2243-4. PubMed ID: 1295471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.